11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity.
We have prepared three analogues of 16 alpha-fluoroestradiol (FES) substituted either with an 11 beta-methoxy group (1, 11 beta-MeO-FES), an 11 beta-ethyl group (2, 11 beta-Et-FES), or a 17 alpha-ethynyl group (3, 17 alpha-ethynyl-FES). These substituents all lower the binding of FES to the serum proteins alphafetoprotein and sex steroid binding protein, but their effect on estrogen receptor binding varies: Receptor binding is increased by the 11 beta-ethyl and 17 alpha-ethynyl groups, but decreased by the 11 beta-methoxy group. These substituents also have a parallel effect on the lipophilicity, and hence the nonspecific binding estimated for these compounds. All three compounds were prepared in fluorine-18 labeled form, at effective specific activities of 90-1600 Ci/mmol, by fluoride ion displacement reactions as done previously with FES. Tissue distribution studies in immature rats show high uptake selectivity by target tissue (uterus) and effective competition by an excess of unlabeled estradiol. Percent injected dose per gram values (% ID/g) at 1 h are 6% for 11 beta-MeO-FES and 11-13% for 11 beta-Et-FES and 17 alpha-ethynyl-FES (FES itself has a % ID/g of 9%). Uptake selectivity in terms of uterus to blood or muscle ratios at 1 h is highest for 11 beta-MeO-FES and 17 alpha-ethynyl-FES (43-149). Metabolic consumption studies show that most activity in uterus is unmetabolized and in blood is rapidly and nearly completely metabolized. In muscle, FES and the substituted estrogens show intermediate levels of metabolic consumption; in some cases activity in muscle extracts is nearly unmetabolized. Thus, the substituents on FES cause major alterations in receptor and nonreceptor binding affinity, uptake efficiency and selectivity, and extent of metabolism. It is not readily clear, however, whether the alterations in uptake efficiency and selectivity are the result of differences in receptor or nonreceptor binding or lipophilicity, or altered patterns of metabolism. Nevertheless, these compounds should be useful in providing a spectrum of uptake properties that could be used for imaging different estrogen-receptor-containing structures.
Pomper
M G
MG
Department of Chemistry, University of Illinois, Urbana 61801.
VanBrocklin
H
H
Thieme
A M
AM
Thomas
R D
RD
Kiesewetter
D O
DO
Carlson
K E
KE
Mathias
C J
CJ
Welch
M J
MJ
Katzenellenbogen
J A
JA
D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004958:Estradiol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D005260:Female; D005462:Fluorine Radioisotopes; D007700:Kinetics; D015394:Molecular Structure; D009132:Muscles / Q000378:metabolism; D000442:Octanols; D051381:Rats; D011960:Receptors, Estrogen / Q000378:metabolism*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D014018:Tissue Distribution; D014599:Uterus / Q000378:metabolism; D014867:Water; D000509:alpha-Fetoproteins / Q000378:metabolism
D005462:Fluorine Radioisotopes; D000442:Octanols; D011960:Receptors, Estrogen; D012738:Sex Hormone-Binding Globulin; D000509:alpha-Fetoproteins; D014867:Water; C066615:11-methoxy-16-fluoroestradiol; C066616:11-ethyl-16-fluoroestradiol; D004958:Estradiol; C066617:17-ethynyl-16-fluoroestradiol